Background: Gastrointestinal (GI) cancers are common and fatal. Improved cancer-directed therapies, with thier substantial role in improving cancer-specific survival, may increase non-cancer mortality-including cardiovascular mortality-in these patients.
Aim: To identify the risk factors of cardiovascular mortality in GI adenocarcinoma patients.